

Dosimetry in isolation perfusion of the limbs by assessment of the severity of grading of toxic tissue reactions

European Journal of Cancer & Clinical Oncology
18, 905-910

DOI: 10.1016/0277-5379(82)90235-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	High-flow isolation perfusion of the rat hind limb in vivo. Journal of Surgical Oncology, 1982, 21, 249-257.	1.7	9
2	Improved tissue perfusion during pressure-regulated hyperthermic regional isolated perfusion in dogs. Journal of Surgical Oncology, 1984, 26, 69-76.	1.7	14
3	Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Cancer, 1985, 55, 698-701.	4.1	22
4	Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer, 1985, 55, 1455-1461.	4.1	34
5	The safe use of cisplatin in hyperthermic isolated limb perfusion systems. Cancer, 1985, 56, 742-744.	4.1	18
6	An update on therapeutic uses of radiotracers in neoplastic disease. Seminars in Nuclear Medicine, 1985, 15, 21-27.	4.6	3
7	Regional perfusion: Current sophistication, what next?. Cancer, 1986, 57, 416-432.	4.1	115
8	Isolated regional perfusion in malignant melanoma of the extremities. World Journal of Surgery, 1987, 11, 527-533.	1.6	42
9	Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. Journal of Surgical Oncology, 1987, 35, 170-172.	1.7	17
10	Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer, 1987, 60, 1703-1707.	4.1	83
11	Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas. World Journal of Surgery, 1988, 12, 345-348.	1.6	17
12	A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. Cancer Chemotherapy and Pharmacology, 1988, 21, 156-162.	2.3	20
13	To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater.. Journal of Clinical Oncology, 1988, 6, 701-708.	1.6	53
14	Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World Journal of Surgery, 1989, 13, 598-602.	1.6	66
15	Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer, 1989, 63, 1092-1096.	4.1	44
16	Prognostic variables in recurrent limb melanoma treated with hyperthermic antitlastic perfusion. Cancer, 1989, 63, 2551-2561.	4.1	114
17	Intractible cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with 1-phenylalanine-mustard (melphalan, L-pam). Cancer, 1989, 64, 392-395.	4.1	14
18	Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer, 1989, 64, 616-621.	4.1	104

#	ARTICLE	IF	CITATIONS
19	Isolated limb perfusion with chemotherapeutic agents for melanoma: A reevaluation of drug dosimetry. European Journal of Cancer & Clinical Oncology, 1989, 25, 1393-1397.	0.7	6
20	Temperature distribution and pH changes during hyperthermic regional isolation perfusion. European Journal of Cancer & Clinical Oncology, 1989, 25, 1157-1163.	0.7	15
22	Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. Cancer Chemotherapy and Pharmacology, 1991, 29, 155-158.	2.3	5
23	Adriamycin in hyperthermic perfusion for advanced limb sarcomas. Annals of Oncology, 1992, 3, S111-S113.	1.2	8
24	Groin Dissection in the Treatment of Lower-Extremity Melanoma Short-term and Long-term Morbidity. Archives of Surgery, 1992, 127, 281.	2.2	107
25	Hyperthermic antitlastic perfusion for the treatment of soft tissue limb sarcoma. Annals of Oncology, 1992, 3, S71-S74.	1.2	13
26	Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. British Journal of Cancer, 1992, 65, 898-902.	6.4	32
27	Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. European Journal of Cancer, 1992, 28, 1811-1813.	2.8	21
28	High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.. Journal of Clinical Oncology, 1992, 10, 52-60.	1.6	707
29	Hyperthermic antitlastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. Journal of Surgical Oncology, 1992, 8, 374-380.	1.4	10
30	The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. British Journal of Cancer, 1992, 66, 159-166.	6.4	29
31	Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World Journal of Surgery, 1992, 16, 227-233.	1.6	124
32	In transit metastases of malignant melanoma treated by high dose rTNF α in combination with interferon- γ and melphalan in isolation perfusion. World Journal of Surgery, 1992, 16, 234-240.	1.6	129
33	Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World Journal of Surgery, 1992, 16, 241-245.	1.6	22
34	A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer, 1993, 71, 2990-2994.	4.1	34
35	Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer, 1993, 72, 1224-1229.	4.1	51
36	Adjuvant regional isolated perfusion with melphalan for patients with clark V melanoma of the extremities. Journal of Surgical Oncology, 1993, 52, 249-254.	1.7	9
38	Isolated hyperthermic limb perfusion for soft tissue sarcoma. Acta Chirurgica Austriaca, 1993, 25, 257-259.	0.2	0

#	ARTICLE	IF	CITATIONS
39	Regional therapy of melanoma. <i>European Journal of Cancer</i> , 1993, 29, 606-612.	2.8	76
40	Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. <i>European Journal of Cancer</i> , 1993, 29, 325-328.	2.8	39
41	Comparison Between the Use of Whole Blood Versus a Diluted Perfusate in Regional Isolated Perfusion by Continuous Monitoring of Transcutaneous Oxygen Tension: A Pilot Study. <i>Journal of Investigative Surgery</i> , 1994, 7, 249-258.	1.3	10
42	Management of recurrent cutaneous melanoma. <i>Current Problems in Cancer</i> , 1994, 18, 145-186.	2.0	14
43	Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. <i>Cancer</i> , 1994, 73, 483-492.	4.1	75
44	Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. <i>Cancer</i> , 1994, 73, 2140-2146.	4.1	78
45	Rationale for using TNF α and chemotherapy in regional therapy of melanoma. <i>Journal of Cellular Biochemistry</i> , 1994, 56, 52-61.	2.6	48
46	Surgical limb perfusion for extremity melanoma. <i>Surgical Oncology</i> , 1994, 3, 91-102.	1.6	13
47	Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. <i>American Journal of Surgery</i> , 1994, 167, 618-620.	1.8	45
48	Regional Chemotherapy for Melanoma A 35-Year Experience. <i>Annals of Surgery</i> , 1994, 220, 520-535.	4.2	72
49	Systemic and Hemodynamic Effects of Recombinant Tumor Necrosis Factor Alpha in Isolation Perfusion of the Limbs. <i>Chest</i> , 1995, 107, 1074-1082.	0.8	51
50	Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival. <i>World Journal of Surgery</i> , 1995, 19, 363-368.	1.6	31
51	Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 1995, 2, 61-70.	1.5	14
52	Long-term Morbidity After Regional Isolated Perfusion With Melphalan for Melanoma of the Limbs. <i>Archives of Surgery</i> , 1995, 130, 43.	2.2	73
53	A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. <i>European Journal of Cancer</i> , 1995, 31, 58-63.	2.8	48
54	Acute hypovolemia after weaning from isolated limb perfusion. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1995, 9, 722-724.	1.3	1
55	ISOLATED HYPERTHERMIA CHEMOTHERAPY PERFUSION FOR LIMB MELANOMA. <i>Surgical Clinics of North America</i> , 1996, 76, 1313-1330.	1.5	21
56	Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. <i>American Journal of Surgery</i> , 1996, 171, 416-420.	1.8	13

#	ARTICLE	IF	CITATIONS
57	A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. European Journal of Cancer, 1996, 32, 1668-1673.	2.8	23
58	A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. European Journal of Cancer, 1996, 32, 2082-2087.	2.8	5
59	Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. European Journal of Surgical Oncology, 1996, 22, 147-151.	1.0	20
60	Systemic toxicity after isolated limb perfusion with melphalan for melanoma. European Journal of Surgical Oncology, 1996, 22, 521-527.	1.0	41
61	Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. European Journal of Surgical Oncology, 1996, 22, 528-531.	1.0	26
62	Leakage measurement during selective limb perfusion using a gamma probe. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 534-538.	2.1	10
63	Treatment of Recurrent Sarcoma of the Extremities by Isolated Limb Perfusion Using Tumor Necrosis Factor Alpha and Melphalan. Tumori, 1996, 82, 579-584.	1.1	25
64	Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.. Journal of Clinical Oncology, 1996, 14, 2653-2665.	1.6	384
65	Treatment of melanoma in-transit metastases confined to the limb. Acta Chirurgica Austriaca, 1996, 28, 9-13.	0.2	17
66	Limb-sparing treatment for soft tissue sarcomas: Influence of prognostic factors. , 1996, 63, 3-8.		23
67	Isolated limb perfusion for malignant melanoma. , 1996, 12, 416-428.		52
68	Frequency and Duration of Remission After Isolated Limb Perfusion for Melanoma. Archives of Surgery, 1997, 132, 903.	2.2	102
69	Rhabdomyolysis and renal function impairment after isolated limb perfusionâ€”Comparison between the effects of perfusion with rhTNFÎ± and a â€œtriple-drugâ€™ regimen. European Journal of Cancer, 1997, 33, 596-601.	2.8	24
70	Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusionâ€”an experimental study in dogs. European Journal of Surgical Oncology, 1997, 23, 439-444.	1.0	7
71	Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Annals of Surgical Oncology, 1997, 4, 440-445.	1.5	31
72	Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Annals of Surgical Oncology, 1997, 4, 64-69.	1.5	70
73	Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Annals of Surgical Oncology, 1997, 4, 88-94.	1.5	29
75	Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha Â± interferon gamma and melphalan in patients with irresectable soft tissue tumors. , 1997, 65, 88-94.		24

#	ARTICLE	IF	CITATIONS
76	High dose tumor necrosis factor- γ and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. , 1997, 79, 1129-1137.		131
77	Isolated limb perfusion in primary and recurrent melanoma: Indications and results. , 1998, 14, 202-209.		61
78	Toxicity and morbidity of isolated limb perfusion. , 1998, 14, 224-231.		65
79	Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Journal of Surgical Oncology, 1998, 14, 238-247.	1.4	194
80	Vascular complications of isolated limb perfusion. European Journal of Surgical Oncology, 1998, 24, 288-291.	1.0	19
81	Clinical Management and Current Research in Isolated Limb Perfusion for Sarcoma and Melanoma. Oncology, 1998, 55, 89-102.	1.9	19
82	Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.. Journal of Clinical Oncology, 1998, 16, 2906-2912.	1.6	240
83	Hyperthermic Isolated Limb Perfusion with TNF α and Cisplatin in the Treatment of Osteosarcoma of the Extremities: A Feasibility Study in Healthy Dogs. Sarcoma, 1999, 3, 89-94.	1.3	3
84	Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Current Problems in Surgery, 1999, 36, 842-908.	1.1	11
85	Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. Journal of the American College of Surgeons, 1999, 188, 522-530.	0.5	55
86	Soft tissue limb sarcomas. , 1999, 86, 1742-1749.		79
87	Multifocal soft tissue sarcoma: Limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. , 1999, 70, 185-189.		28
88	Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. European Journal of Surgical Oncology, 1999, 25, 503-508.	1.0	30
89	Isolated limb perfusion with tumour necrosis factor- α and melphalan for unresectable bone sarcomas of the lower extremity. European Journal of Surgical Oncology, 1999, 25, 509-514.	1.0	34
90	Limb desmoid tumors: A possible role for isolated limb perfusion with tumor necrosis factor- α and melphalan. Surgery, 1999, 126, 963-967.	1.9	38
91	Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor α and Melphalan for Kaposi Sarcoma. Archives of Surgery, 1999, 134, 177.	2.2	26
92	Management of regional metastases. Clinical and Experimental Dermatology, 2000, 25, 490-496.	1.3	0
93	Isolated limb perfusion: is it a useful technique or a futile last gasp?. Journal of Surgical Education, 2000, 57, 209-214.	0.7	1

#	ARTICLE	IF	CITATIONS
94	The Use Of Isolated Limb Perfusion To Manage Recurrent Malignant Melanoma. Clinics in Plastic Surgery, 2000, 27, 441-450.	1.5	5
95	Giant melanoma of the left thumb. European Journal of Surgical Oncology, 2000, 26, 189-190.	1.0	4
96	Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. European Journal of Surgical Oncology, 2000, 26, 213-221.	1.0	14
97	Limb salvage by neoadjuvant isolated perfusion with TNF α and melphalan for non-resectable soft tissue sarcoma of the extremities. European Journal of Surgical Oncology, 2000, 26, 669-678.	1.0	103
98	Hyperthermic isolated regional perfusion of the limb with carboplatin. European Journal of Surgical Oncology, 2000, 26, 792-797.	1.0	20
99	Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. British Journal of Cancer, 2001, 85, 157-165.	6.4	39
100	Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan alone. European Journal of Surgical Oncology, 2001, 27, 390-395.	1.0	63
101	Isolated Limb Perfusion. Surgical Oncology Clinics of North America, 2001, 10, 821-832.	1.5	38
102	Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Research, 2001, 11, 423-431.	1.2	29
103	Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives. Current Oncology Reports, 2001, 3, 359-367.	4.0	51
104	Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients. Journal of Clinical Oncology, 2002, 20, 3282-3292.	1.6	43
105	Stop-flow technique for loco-regional delivery of antineoplastic agents: literature review and personal experience. European Journal of Surgical Oncology, 2002, 28, 544-553.	1.0	17
106	Isolated limb perfusion in locally advanced cutaneous melanoma. Seminars in Oncology, 2002, 29, 400-409.	2.2	48
107	Isolated limb perfusion with melphalan for femoral metastases of breast cancer: Case report. Journal of Surgical Oncology, 2002, 81, 209-212.	1.7	4
108	³¹ P-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer, 2002, 94, 1557-1564.	4.1	35
109	Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Annals of Surgical Oncology, 2002, 9, 127-136.	1.5	118
110	Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor- α and melphalan. Annals of Surgical Oncology, 2002, 9, 355-363.	1.5	24
111	Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Annals of Surgical Oncology, 2002, 9, 968-974.	1.5	60

#	ARTICLE	IF	CITATIONS
112	Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. <i>Annals of Surgical Oncology</i> , 2002, 9, 1004-1009.	1.5	47
113	Fifty Tumor Necrosis Factor-Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors. <i>Annals of Surgical Oncology</i> , 2003, 10, 32-37.	1.5	58
114	Isolated limb perfusion with tumor necrosis factor- α and melphalan for patients with unresectable soft tissue sarcoma of the extremities. <i>Cancer</i> , 2003, 98, 1483-1490.	4.1	85
115	Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 469-483.	1.5	16
116	The role of isolated limb perfusion for melanoma confined to the extremities. <i>Surgical Clinics of North America</i> , 2003, 83, 371-384.	1.5	22
117	Pentoxifyllin Attenuates the Systemic Inflammatory Response Induced During Isolated Limb Perfusion With Recombinant Human Tumor Necrosis Factor- α and Melphalan. <i>Annals of Surgical Oncology</i> , 2003, 10, 562-568.	1.5	15
118	Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. <i>American Journal of Surgery</i> , 2003, 186, 460-467.	1.8	31
119	Prognostic factors for survival after isolated limb perfusion for malignant melanoma. <i>European Journal of Surgical Oncology</i> , 2003, 29, 916-921.	1.0	17
120	Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. <i>Lancet Oncology</i> , The, 2003, 4, 359-364.	10.7	41
121	Current uses of isolated limb perfusion in the clinic and a model system for new strategies. <i>Lancet Oncology</i> , The, 2003, 4, 429-437.	10.7	232
122	Solid Tumor Therapy: Manipulation of the Vasculature with TNF. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 195-203.	1.9	16
123	Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma. <i>Melanoma Research</i> , 2003, 13, 51-58.	1.2	21
124	TNF- α -Based Isolated Perfusion for Limb-Threatening Soft Tissue Sarcomas: State of the Art and Future Trends. <i>Journal of Immunotherapy</i> , 2003, 26, 291-300.	2.4	23
125	Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. <i>Melanoma Research</i> , 2003, 13, 395-399.	1.2	22
126	Phase I-II study on isolation antitumor fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. <i>Melanoma Research</i> , 2003, 13, 293-297.	1.2	4
127	TNF-based isolated limb perfusion: A decade of experience with antivasculature therapy in the management of locally advanced extremity soft tissue sarcomas. <i>Cancer Treatment and Research</i> , 2004, 120, 65-79.	0.5	24
128	Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity. <i>Clinical Cancer Research</i> , 2004, 10, 6879-6886.	7.0	21
129	Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. <i>Annals of Oncology</i> , 2004, 15, iv107-iv112.	1.2	16

#	ARTICLE	IF	CITATIONS
130	Synergistic Antitumor Activity of Histamine Plus Melphalan in Isolated Limb Perfusion: Preclinical Studies. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1603-1610.	6.3	34
131	Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor- α and Melphalan for Bulky In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2004, 11, 173-177.	1.5	69
132	Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 491-499.	1.5	34
133	Management of in-transit melanoma of the extremity with isolated limb perfusion. <i>Current Treatment Options in Oncology</i> , 2004, 5, 173-184.	3.0	37
134	Management of in-transit metastases from cutaneous malignant melanoma. <i>British Journal of Surgery</i> , 2004, 91, 673-682.	0.3	66
135	Perfusión de extremidad aislada en sarcomas de partes blandas irresecables: un nuevo estándar. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2004, 48, 57-64.	0.1	1
136	Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. <i>European Journal of Surgical Oncology</i> , 2004, 30, 433-439.	1.0	35
137	Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. <i>European Journal of Surgical Oncology</i> , 2004, 30, 1107-1112.	1.0	45
138	Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. <i>American Journal of Surgery</i> , 2004, 188, 532-537.	1.8	25
139	One Hundred Consecutive Isolated Limb Perfusions With TNF- α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases. <i>Annals of Surgery</i> , 2004, 240, 939-948.	4.2	111
140	Tumor Vascular Therapy With TNF: Critical Review on Animal Models. , 2004, 98, 227-246.		11
141	Isolated Limb Perfusion for Unresectable Melanoma of the Extremities. <i>Archives of Surgery</i> , 2004, 139, 1237.	2.2	74
142	Predictors of Outcome After Hyperthermic Isolated Limb Perfusion. <i>Archives of Surgery</i> , 2005, 140, 1115.	2.2	42
143	Isolated Limb Perfusion With Tumor Necrosis Factor and Melphalan Prevents Amputation in Patients With Multiple Sarcomas in Arm or Leg. <i>Annals of Surgical Oncology</i> , 2005, 12, 473-479.	1.5	33
144	Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure. <i>Annals of Surgical Oncology</i> , 2005, 12, 609-615.	1.5	52
145	Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs. <i>Annals of Surgical Oncology</i> , 2005, 12, 406-411.	1.5	54
146	Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. <i>Annals of Surgical Oncology</i> , 2005, 12, 398-405.	1.5	41
147	Systemic leakage during isolated limb perfusion for melanoma. <i>British Journal of Surgery</i> , 2005, 80, 1124-1126.	0.3	64

#	ARTICLE	IF	CITATIONS
148	Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma. British Journal of Surgery, 2005, 82, 1343-1345.	0.3	16
149	Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. Journal of Surgical Oncology, 2005, 91, 107-111.	1.7	27
150	Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility. Cancer Chemotherapy and Pharmacology, 2005, 56, 55-62.	2.3	3
151	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF- α be better?. Annals of Oncology, 2005, 16, 1061-1068.	1.2	115
152	TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. European Journal of Surgical Oncology, 2005, 31, 912-916.	1.0	32
153	TNF dose reduction in isolated limb perfusion. European Journal of Surgical Oncology, 2005, 31, 1011-1019.	1.0	50
154	Technology Insight: utility of TNF- α -based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature Clinical Practice Oncology, 2006, 3, 94-103.	4.3	80
155	Isolated Limb Perfusion in Regional Melanoma. Surgical Oncology Clinics of North America, 2006, 15, 373-384.	1.5	7
156	A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2006, 13, 1123-1129.	1.5	77
158	Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. European Journal of Surgical Oncology, 2006, 32, 224-227.	1.0	40
159	Repeat isolated limb perfusion with TNF- α and melphalan for recurrent limb melanoma after failure of previous perfusion. European Journal of Surgical Oncology, 2006, 32, 318-324.	1.0	49
160	Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor- α . European Journal of Surgical Oncology, 2006, 32, 371-380.	1.0	62
161	Soft tissue sarcoma. Update on Cancer Therapeutics, 2006, 1, 385-402.	0.4	3
162	Palliation of Skeletal Melanoma Metastases with Isolated Limb Perfusion Chemotherapy. Dermatologic Surgery, 2006, 32, 1199-1201.	0.8	0
163	Hyperthermic isolated limb perfusion: evolving concepts in the treatment of extremity soft tissue sarcomas. Current Opinion in Orthopaedics, 2006, 17, 558-562.	0.3	2
164	Palliation of Skeletal Melanoma Metastases with Isolated Limb Perfusion Chemotherapy. Dermatologic Surgery, 2006, 32, 1199-1201.	0.8	3
165	Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors. Critical Reviews in Oncology/Hematology, 2006, 60, 112-130.	4.4	17
166	Isolated Limb Perfusion With Melphalan and Tumor Necrosis Factor α for Advanced Melanoma and Soft-Tissue Sarcoma. Annals of Surgical Oncology, 2006, 14, 230-238.	1.5	67

#	ARTICLE	IF	CITATIONS
168	The palliative value of tumor necrosis factor α -based isolated limb perfusion in patients with metastatic sarcoma and melanoma. <i>Cancer</i> , 2006, 106, 156-162.	4.1	74
169	Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor- α and melphalan for limb-threatening soft tissue sarcoma. <i>Cancer</i> , 2006, 106, 1776-1784.	4.1	132
170	Optimizing a Novel Regional Chemotherapeutic Agent against Melanoma: Hyperthermia-Induced Enhancement of Temozolomide Cytotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 289-297.	7.0	42
171	Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma. <i>Annals of Surgery</i> , 2007, 245, 591-596.	4.2	85
172	The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. <i>European Journal of Surgical Oncology</i> , 2007, 33, 776-782.	1.0	49
173	Prognostic Scoring in Patients With Melanoma After Adjuvant Isolated Limb Perfusion. <i>Journal of Surgical Research</i> , 2007, 138, 22-24.	1.6	5
174	Preoperative Isolated Limb Infusion of Doxorubicin and External Irradiation for Limb-Threatening Soft Tissue Sarcomas. <i>Annals of Surgical Oncology</i> , 2007, 14, 568-576.	1.5	44
175	Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 553-559.	1.5	61
176	Isolated Limb Perfusion with Melphalan and TNF- α in the Treatment of Extremity Sarcoma. <i>Current Treatment Options in Oncology</i> , 2007, 8, 417-427.	3.0	63
177	Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: Long-term results on efficacy and limb salvage in a selected group of patients. <i>Journal of Surgical Oncology</i> , 2008, 98, 148-155.	1.7	48
178	TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 1218-1223.	1.5	17
179	Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2008, 15, 2749-2756.	1.5	48
180	Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience. <i>Annals of Surgical Oncology</i> , 2008, 15, 3003-3013.	1.5	146
181	Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion. <i>Annals of Surgical Oncology</i> , 2008, 15, 2195-2205.	1.5	144
182	Isolated Limb Perfusion for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 785-794.	1.5	23
183	Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. <i>International Journal of Hyperthermia</i> , 2008, 24, 275-289.	2.5	48
184	Regional Chemotherapy: Overview. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 709-730.	1.5	16
185	Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 731-758.	1.5	7

#	ARTICLE	IF	CITATIONS
186	Toxicity and morbidity after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: The experience of the Tuscan Reference Centre. Journal of Experimental and Clinical Cancer Research, 2008, 27, 67.	8.6	8
187	History of regional chemotherapy for cancer of the extremities. International Journal of Hyperthermia, 2008, 24, 185-192.	2.5	11
188	Extremity Perfusion for Sarcoma. Surgical Oncology Clinics of North America, 2008, 17, 805-824.	1.5	14
189	Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?. Oncologist, 2008, 13, 175-186.	3.7	62
190	Current status of isolated limb infusion with mild hyperthermia for melanoma. International Journal of Hyperthermia, 2008, 24, 219-225.	2.5	13
191	Current status of hyperthermic limb perfusion for in-transit melanoma. International Journal of Hyperthermia, 2008, 24, 205-217.	2.5	8
192	Effectiveness of regional chemotherapy with TNF- α /Melphalan in advanced soft tissue sarcoma of the extremities. International Journal of Hyperthermia, 2008, 24, 193-203.	2.5	39
193	The European approach to in-transit melanoma lesions. International Journal of Hyperthermia, 2008, 24, 227-237.	2.5	19
194	Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma. Cancer Control, 2008, 15, 225-232.	1.8	54
195	A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US. Journal of the American College of Surgeons, 2009, 208, 706-715.	0.5	132
196	Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer, 2009, 115, 1932-1940.	4.1	55
197	Isolated limb infusion: A review. Journal of Surgical Oncology, 2009, 100, 169-177.	1.7	42
199	Revolutionizing the treatment of locally advanced extremity soft tissue sarcomas: a review on TNF α -based isolated limb perfusion. European Surgery - Acta Chirurgica Austriaca, 2009, 41, 176-188.	0.7	3
201	Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity?. Annals of Surgical Oncology, 2009, 16, 953-961.	1.5	45
202	Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients. Annals of Surgical Oncology, 2009, 16, 1184-1192.	1.5	52
203	Isolated Limb Infusion as Palliative Treatment for Advanced Limb Disease in Patients with AJCC Stage IV Melanoma. Annals of Surgical Oncology, 2009, 16, 1193-1201.	1.5	21
204	Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. Annals of Surgical Oncology, 2009, 16, 2570-2578.	1.5	55
205	Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome. Annals of Surgical Oncology, 2009, 16, 3463-3472.	1.5	37

#	ARTICLE	IF	CITATIONS
206	Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1Âmg and Melphalan (T1-M HILP) Is Safe and Efficient. <i>Annals of Surgical Oncology</i> , 2009, 16, 3350-3357.	1.5	86
207	Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. <i>European Journal of Surgical Oncology</i> , 2009, 35, 209-214.	1.0	20
208	Common peroneal nerve palsy following TNF-based isolated limb perfusion for irresectable extremity desmoid tumor. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2009, 95, 639-644.	2.0	8
209	Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1611-1630.	2.4	47
210	Isolated Limb Infusion: Technique Description and Clinical Application. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 837-841.	0.5	5
212	Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma. <i>Annals of Surgery</i> , 2009, 249, 1008-1013.	4.2	26
213	Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. <i>Melanoma Research</i> , 2009, 19, 106-111.	1.2	26
214	Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: Feasibility and reproducibility in a multi-institutional Hellenic collaborative study. <i>Oncology Reports</i> , 2010, 23, 1077-83.	2.6	11
215	Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 3000-3007.	1.5	35
216	Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety. <i>Oncologist</i> , 2010, 15, 416-427.	3.7	113
217	Strategies for Targeting Tumors and Tumor Vasculature for Cancer Therapy. <i>Advances in Genetics</i> , 2010, 69, 135-152.	1.8	11
218	Pharmacotherapy of regional melanoma therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 79-93.	1.8	7
219	Apoptotic and necrotic effects of tumour necrosis factor-alpha potentiated with hyperthermia on L929 and tumour necrosis factor-alpha-resistant L929. <i>International Journal of Hyperthermia</i> , 2010, 26, 556-564.	2.5	10
220	Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. <i>International Journal of Hyperthermia</i> , 2010, 26, 16-20.	2.5	28
221	Use of an automated circuit for isolated limb infusion for malignancy. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1215-1219.	1.0	0
222	Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1039-1045.	3.3	7
223	Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1033-1037.	3.3	2
224	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1383-1394.	3.3	7

#	ARTICLE	IF	CITATIONS
226	Technique and outcomes of isolated limb infusion for locally advanced malignant melanoma – A radiological perspective. <i>Clinical Radiology</i> , 2011, 66, 1175-1180.	1.1	3
227	Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. <i>Current Opinion in Oncology</i> , 2011, 23, 183-188.	2.4	28
228	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. <i>Archives of Surgery</i> , 2011, 146, 870.	2.2	38
229	Isolated Limb Perfusion and Isolated Limb Infusion for Malignant Lesions of the Extremities. <i>Current Problems in Surgery</i> , 2011, 48, 371-430.	1.1	19
230	Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2011, 213, 306-316.	0.5	91
231	Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 1877-1883.	1.5	29
233	Initial experiences with isolated limb perfusion for unresectable melanoma of the limb. <i>Irish Journal of Medical Science</i> , 2011, 180, 517-520.	1.5	3
234	Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases. <i>Journal of Surgical Oncology</i> , 2011, 104, 718-723.	1.7	6
235	Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. <i>Journal of Surgical Oncology</i> , 2011, 104, 397-404.	1.7	37
236	Isolated limb perfusion for unresectable extremity sarcoma. <i>Cancer</i> , 2011, 117, 3235-3241.	4.1	24
237	Long-term outcome of isolated limb perfusion with tumour necrosis factor- α for patients with melanoma in-transit metastases. <i>British Journal of Surgery</i> , 2011, 98, 1573-1580.	0.3	51
238	Long-Term Results of Tumor Necrosis Factor α and Melphalan-Based Isolated Limb Perfusion in Locally Advanced Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 4036-4044.	1.6	87
240	A novel mouse model of isolated limb perfusion for extremity melanoma. <i>Journal of Surgical Research</i> , 2012, 178, 294-298.	1.6	6
241	Is Melphalan Dose Adjustment According to Ideal Body Weight Useful in Isolated Limb Infusion for Melanoma?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3050-3056.	1.5	19
242	Fluorescein Angiographic Findings after Intra-arterial Chemotherapy for Retinoblastoma. <i>Ophthalmology</i> , 2012, 119, 843-849.	5.2	63
243	Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 287-299.	1.5	5
244	Progression of cutaneous melanoma: implications for treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 775-796.	3.3	32
245	Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity. <i>Clinics</i> , 2012, 67, 237-241.	1.5	12

#	ARTICLE	IF	CITATIONS
246	20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters. <i>Annals of Surgical Oncology</i> , 2012, 19, 627-635.	1.5	61
247	Isolated limb perfusion with TNF- α and melphalan for distal parts of the limb in soft tissue sarcoma patients. <i>Journal of Surgical Oncology</i> , 2012, 105, 563-569.	1.7	22
248	Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials. <i>Journal of Surgical Oncology</i> , 2012, 106, 921-928.	1.7	22
250	A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities. <i>Annals of Surgical Oncology</i> , 2012, 19, 1637-1643.	1.5	40
251	Long-Term Outcome of Isolated Limb Perfusion in Advanced Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2012, 19, 1800-1807.	1.5	17
252	Quality of Life Outcomes after Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2012, 19, 1373-1378.	1.5	11
253	Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 173-179.	1.7	72
254	Integrating Chemotherapy to Surgery: Novel Approaches in Regionally Aggressive Cancer Metastasis. , 2013, , 319-350.		0
255	Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases. <i>BMC Anesthesiology</i> , 2013, 13, 15.	1.8	11
256	Alterations of Circulating Bone Marrow-Derived VEGFR-2+ Progenitor Cells in Isolated Limb Perfusion With or Without rhTNF- α . <i>Annals of Surgical Oncology</i> , 2013, 20, 3694-3701.	1.5	1
257	Isolated limb perfusion of soft tissue sarcomas: A comprehensive review of literature. <i>Cancer Treatment Reviews</i> , 2013, 39, 569-577.	7.7	16
258	Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: A systematic review. <i>European Journal of Surgical Oncology</i> , 2013, 39, 311-319.	1.0	48
259	Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. <i>International Journal of Hyperthermia</i> , 2013, 29, 551-557.	2.5	42
260	The use of isolated limb infusion in limb threatening extremity sarcomas. <i>International Journal of Hyperthermia</i> , 2013, 29, 1-7.	2.5	14
261	Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. <i>Cancer Management and Research</i> , 2013, 5, 243.	1.9	17
262	Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. <i>British Journal of Surgery</i> , 2014, 101, 1674-1680.	0.3	34
264	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. <i>Journal of Surgical Oncology</i> , 2014, 109, 405-409.	1.7	23
265	Isolated limb perfusion for in-transit melanoma metastases: Melphalan or TNF-melphalan perfusion?. <i>Journal of Surgical Oncology</i> , 2014, 109, 338-347.	1.7	26

#	ARTICLE	IF	CITATIONS
266	Isolated limb infusion: Technical aspects. Journal of Surgical Oncology, 2014, 109, 352-356.	1.7	23
267	Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review. Journal of Surgical Oncology, 2014, 109, 348-351.	1.7	52
268	Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 780-785.	1.7	23
269	Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity. ANZ Journal of Surgery, 2014, 84, 677-682.	0.7	11
270	Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. Journal of Surgical Oncology, 2014, 109, 786-790.	1.7	34
271	Isolated limb perfusion with melphalan for melanoma. Journal of Surgical Oncology, 2014, 109, 332-337.	1.7	36
272	Locoregional Therapies in Melanoma. Surgical Clinics of North America, 2014, 94, 1003-1015.	1.5	27
273	Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation. World Journal of Surgical Oncology, 2014, 12, 81.	1.9	13
274	Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma. Annals of Surgical Oncology, 2015, 22, 356-361.	1.5	26
275	Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. Clinical Physiology and Functional Imaging, 2015, 35, 301-305.	1.2	6
276	Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma Research, 2015, 25, 427-431.	1.2	14
277	Perfusion and Infusion for Melanoma In-Transit Metastases in the Era of Effective Systemic Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e528-e534.	3.8	19
278	Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma. Plastic Surgery, 2015, 23, 25-30.	1.0	5
279	Treatment modifications in tumour necrosis factor- α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. European Journal of Cancer, 2015, 51, 367-373.	2.8	24
280	Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). Surgery Today, 2015, 45, 355-362.	1.5	3
281	Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. Annals of Surgical Oncology, 2015, 22, 482-488.	1.5	36
282	Regional Therapies for In-transit Disease. Surgical Oncology Clinics of North America, 2015, 24, 309-322.	1.5	9
283	Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. Cancer Research, 2016, 76, 6620-6630.	0.9	20

#	ARTICLE	IF	CITATIONS
284	Local Recurrence of Extremity Soft Tissue Sarcoma. Surgical Clinics of North America, 2016, 96, 1157-1174.	1.5	14
285	Isolated limb perfusion as a treatment option for rare types of tumours. International Journal of Hyperthermia, 2016, 32, 595-599.	2.5	10
286	Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared. European Journal of Surgical Oncology, 2016, 42, 1898-1905.	1.0	6
287	Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Annals of Surgical Oncology, 2016, 23, 2330-2335.	1.5	49
288	Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma. Cancer, 2016, 122, 2624-2632.	4.1	38
289	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Annals of Surgical Oncology, 2016, 23, 1096-1103.	1.5	43
290	Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience. International Journal of Hyperthermia, 2016, 32, 165-172.	2.5	26
291	Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. Annals of Surgical Oncology, 2016, 23, 2062-2069.	1.5	15
292	Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. Annals of Surgical Oncology, 2016, 23, 1090-1095.	1.5	3
293	The role of regional chemotherapy in the management of extremity soft tissue malignancies. European Journal of Surgical Oncology, 2016, 42, 7-17.	1.0	15
294	A Single-Center Experience With Isolated Limb Infusion: An Interventional Oncology Opportunity. American Journal of Roentgenology, 2017, 208, 663-668.	2.2	3
295	Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. Journal of the American College of Surgeons, 2017, 224, 635-642.	0.5	21
296	Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients. Annals of Surgical Oncology, 2017, 24, 1997-2005.	1.5	29
297	Lower limb function and quality of life after ILP for soft-tissue sarcoma. World Journal of Surgical Oncology, 2017, 15, 84.	1.9	15
298	Laparoscopic hyperthermic isolated limb perfusion a new minimally invasive approach for HILP. International Journal of Hyperthermia, 2017, 33, 1-5.	2.5	4
299	Myoglobin does not predict local toxicity in isolated limb perfusion. International Journal of Hyperthermia, 2017, 33, 679-683.	2.5	2
300	Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation. Journal of Surgical Research, 2017, 213, 147-157.	1.6	5
301	Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Annals of Surgical Oncology, 2017, 24, 3842-3849.	1.5	32

#	ARTICLE	IF	CITATIONS
302	Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2157-2162.	1.0	12
303	Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. <i>European Journal of Cancer</i> , 2017, 85, 114-121.	2.8	12
304	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 3245-3251.	1.5	16
305	Diagnosis and treatment of in-transit melanoma metastases. <i>European Journal of Surgical Oncology</i> , 2017, 43, 544-560.	1.0	80
306	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	3.4	102
307	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. <i>Annals of Surgical Oncology</i> , 2018, 25, 885-893.	1.5	7
308	Minimally invasive isolated limb perfusion – technical details and initial outcome of a new treatment method for limb malignancies. <i>International Journal of Hyperthermia</i> , 2018, 35, 667-673.	2.5	5
309	Management of Locally and Regionally Recurrent Melanoma. , 2018, , 1-20.		0
310	The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion. <i>Annals of Surgical Oncology</i> , 2018, 25, 1836-1842.	1.5	9
311	The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. <i>European Journal of Cancer</i> , 2018, 100, 46-54.	2.8	10
312	Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy. <i>British Journal of Cancer</i> , 2018, 119, 429-434.	6.4	9
313	Regional therapies for locoregionally advanced and unresectable melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 495-502.	3.3	12
316	Isolated Limb Infusion for Recurrent and Locally Metastatic Limb Melanoma. , 2018, , 451-465.		1
317	Management of Locally and Regionally Recurrent Melanoma. , 2019, , 515-534.		0
318	Patient experiences with isolated limb perfusion for malignant melanoma – A qualitative study. <i>European Journal of Oncology Nursing</i> , 2019, 43, 101672.	2.1	4
319	Is blood a necessary component of the perfusate during isolated limb perfusion – a randomized controlled trial. <i>International Journal of Hyperthermia</i> , 2019, 36, 793-799.	2.5	4
320	Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. <i>Clinical and Translational Oncology</i> , 2019, 21, 1135-1141.	2.4	8
321	Let's Not Forget About Regional Therapy for the Treatment of Locally Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2322-2324.	1.5	0

#	ARTICLE	IF	CITATIONS
322	Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Extremities to Avoid Amputation. Isolated Limb Perfusion is a Valid Option. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2019, 91, 22-32.	0.1	0
323	BRAF status as a predictive factor for response in isolated limb perfusion. International Journal of Hyperthermia, 2019, 36, 510-514.	2.5	2
324	Long-term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. Annals of Surgical Oncology, 2019, 26, 2486-2494.	1.5	35
325	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. European Journal of Surgical Oncology, 2019, 45, 832-837.	1.0	4
326	Soft Tissue Cancer Management: Isolated Limb Infusion for Sarcoma. Visceral Medicine, 2019, 35, 373-379.	1.3	3
327	Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma. Melanoma Management, 2019, 6, MMT26.	0.5	5
328	Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. Annals of Surgical Oncology, 2019, 26, 1055-1062.	1.5	10
329	Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV❼A propensity score matched, single center study. Journal of Surgical Oncology, 2019, 119, 717-727.	1.7	1
330	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Annals of Surgical Oncology, 2020, 27, 35-42.	1.5	4
331	Management of Locoregionally Advanced Melanoma. Surgical Clinics of North America, 2020, 100, 109-125.	1.5	5
332	First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?. European Journal of Surgical Oncology, 2020, 46, 272-276.	1.0	1
333	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	1.0	8
334	RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Molecular Medicine, 2020, 12, e10979.	6.9	22
335	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	1.5	8
336	Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. Scientific Reports, 2020, 10, 13245.	3.3	6
338	Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities. European Journal of Surgical Oncology, 2020, 46, 1315-1319.	1.0	3
339	Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. Cancer Treatment Reviews, 2020, 88, 102058.	7.7	18
340	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10

#	ARTICLE	IF	CITATIONS
341	Isolated limb infusion: Institutional protocol and implementation. Journal of Surgical Oncology, 2020, 122, 99-105.	1.7	7
342	Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis. Oncoimmunology, 2020, 9, 1684126.	4.6	7
344	Molecular Aspects of the Isolated Limb Infusion Procedure. Biomedicines, 2021, 9, 163.	3.2	3
345	In-transit metastatic cutaneous melanoma: current management and future directions. Clinical and Experimental Metastasis, 2022, 39, 201-211.	3.3	6
346	The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies. Melanoma Research, 2021, Publish Ahead of Print, 290-297.	1.2	2
347	Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007â€“2018. Melanoma Research, 2021, 31, 456-463.	1.2	1
348	A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients. Journal of Surgical Research, 2021, 268, 737-747.	1.6	1
349	Current approaches in managing in-transit metastasis of malignant melanoma: a comprehensive review and proposal of an algorithm. European Journal of Plastic Surgery, 2021, 44, 721-732.	0.6	1
350	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. European Journal of Surgical Oncology, 2022, 48, 500-507.	1.0	7
351	Results of isolated limb perfusion for metastasized malignant melanoma. Surgical Oncology, 2021, 38, 101603.	1.6	1
352	Isolated limb perfusion with high-dose tumor necrosis factor- α for locally advanced extremity soft tissue sarcomas. Cancer Treatment and Research, 1997, 91, 189-203.	0.5	20
353	The Role of Hyperthermic Perfusion in the Treatment of Tumors of the Extremities. Advances in Experimental Medicine and Biology, 1990, 267, 223-234.	1.6	4
354	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
355	Infusion Technique. , 2020, , 357-366.		1
356	Isolated Limb Perfusion with TNF- α and Melphalan in Locally Advanced Soft Tissue Sarcomas of the Extremities. Recent Results in Cancer Research, 2009, 179, 257-270.	1.8	25
357	Isolierte ExtremitÄtenperfusion bei Melanomen. , 2013, , 299-311.		1
358	Clinical Practice of Hyperthermic Extremity Perfusion In Combination with Radiotherapy and Chemotherapy. Medical Radiology, 1996, , 323-345.	0.1	2
359	Preliminary Results of a Double Perfusion Schedule with Melphalan in Measurable Melanoma. , 1990, , 192-194.		1

#	ARTICLE	IF	CITATIONS
360	Die isolierte hypertherme Extremitätenperfusion. , 1991, , 178-187.		1
361	Die regionale hypertherme Perfusion – Therapiekonzept und Langzeitergebnisse. , 1992, , 494-501.		5
362	Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas. Annals of Surgery, 1996, 224, 756-765.	4.2	404
363	Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor- α and melphalan. Critical Care Medicine, 2000, 28, 1040-1046.	0.9	44
364	Safety and Efficacy of Isolated Limb Perfusion in Elderly Melanoma Patients. Annals of Surgical Oncology, 2002, 9, 968-974.	1.5	6
365	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers, 2015, 7, 1154-1177.	3.7	20
366	Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World Journal of Clinical Oncology, 2015, 6, 57.	2.3	5
367	Isolated Limb Perfusion for Malignant Melanoma and Soft Tissue Sarcoma. , 2000, , 57-85.		0
368	Regional Therapy of Cancer. , 2001, , 1863-1880.		1
370	Regional Therapy of Cancer Using Continuous Hyperthermic Peritoneal Perfusion or Vascular Isolation and Perfusion Techniques. , 2004, , 327-348.		1
371	Isolated Limb Perfusion for Melanoma in Transit Metastases. , 2007, , 417-426.		0
372	Regional Therapy of Cancer. , 2008, , 2151-2171.		0
373	Isolated Limb Perfusion for Melanoma. , 2011, , 209-220.		0
374	Isolierte Extremitätenperfusion bei Weichgewebesarkomen. , 2011, , 255-263.		0
375	Current Controversies in the Surgical Management of Melanoma. , 0, , .		0
376	Isolierte Extremitätenperfusion bei lokal fortgeschrittenen Weichteilsarkomen. , 2013, , 359-379.		0
377	Isolierte arterielle Infusion von Extremitäten. , 2013, , 313-325.		0
378	Management of In-Transit Malignant Melanoma. , 0, , .		1

#	ARTICLE	IF	CITATIONS
379	Specialized Cancer Procedures and Surgery. , 2014, , 201-218.		0
380	Loco-Regional Drug Delivery in Cancer Treatment, with Special Reference to Isolation Perfusion. , 1987, , 53-76.		1
381	Combined Hyperthermia and Chemotherapy for Malignant Melanoma of the Limbs. , 1990, , 77-88.		3
382	Clinical and Histopathological Aspects of Hyperthermic Isolated Regional Perfusion of Soft Tissue Sarcomas of the Extremities. , 1990, , 272-278.		0
383	Isolated Limb Perfusion. , 1992, , 123-134.		0
385	Die isolierte Extremitätenperfusion beim malignen Melanom. , 1997, , 358-368.		0
386	Oxygen utilization during and after isolated limb perfusion with rhTNF α and melphalan. Langenbecks Archiv Fur Chirurgie, 1997, 382, 128.	0.2	0
387	Isolated limb infusion: efficacy, toxicity and an evolution in the management of in-transit melanoma. Plastic Surgery, 2015, 23, 25-30.	1.0	5
388	Isolated Limb Perfusion for Melanoma. , 2016, , 355-373.		0
389	Induction Treatment in Sarcomas. , 2016, , 391-436.		0
390	Isolated Limb Infusion. , 2016, , 375-390.		0
391	Isolated Limb Perfusion for Locally Advanced Soft Tissue Sarcoma. , 2016, , 437-460.		0
393	Hyperthermic Regional Perfusion for Melanoma of the Limbs. , 2019, , 1-31.		0
394	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
395	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
396	Hyperthermic Isolated Limb Perfusion for Melanoma. , 2020, , 367-378.		0
397	Trial Data for Sarcoma. , 2020, , 395-409.		0
398	Isolated Limb Perfusion on Nonmelanoma Skin Cancer for Limb Salvage: A Series of Four Cases. Cureus, 2020, 12, e9998.	0.5	1

#	ARTICLE	IF	CITATIONS
399	Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature. <i>Cancers</i> , 2021, 13, 5485.	3.7	4
400	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
401	Hyperthermic Regional Perfusion for Melanoma of the Limbs. , 2020, , 795-825.		0
402	Indocyanine Green for Leakage Control in Isolated Limb Perfusion. <i>Journal of Personalized Medicine</i> , 2021, 11, 1152.	2.5	2
404	Isolated Limb Perfusion in Advanced Soft Tissue Sarcomas. , 2007, , 407-415.		1
405	Surgical Strategies. , 2007, , 59-72.		0
406	Locoregional Chemotherapy Including Perfusion. , 2008, , 33-46.		0
408	The diagnostic value of modified systemic \pm inflammation score in predicting post-operative outcomes of cutaneous melanoma patients who underwent \pm isolated limb perfusion. <i>World Journal of Surgical Oncology</i> , 2021, 19, 327.	1.9	1
409	Isolated limb perfusion for locally advanced melanoma in the immunotherapy era. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1288-1292.	1.0	4
412	Locoregional Chemotherapy Including Perfusion. , 2008, , 33-46.		0
414	O ₂ -Utilisation während und nach hyperthermer Extremitätenperfusion mit rhTNF α ... und Melphalan. <i>Langenbecks Archiv Fur Chirurgie</i> , 1997, 382, 128-133.	0.2	1
415	Isolated Limb Perfusion of Upper Limb: How I Do It. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.7	0
417	Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases. <i>Cancers</i> , 2023, 15, 472.	3.7	3
418	Isolated Limb Infusion for Limb-Threatening, Unresectable Sarcoma: Past Progress, Current Applications, and Future Directions. <i>Journal of Clinical Medicine</i> , 2023, 12, 4036.	2.4	0
419	VARIATION IN RESPONSE RATES TO ISOLATED LIMB PERFUSION IN DIFFERENT SOFT TISSUE TUMOR SUBTYPES – AN INTERNATIONAL MULTI-CENTER STUDY. <i>European Journal of Cancer</i> , 2023, , 112949.	2.8	1
420	The Diagnosis and Management of Cutaneous Metastases from Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14535.	4.1	2
421	A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusion. <i>Perfusion (United Kingdom)</i> , 0, , .	1.0	0
422	Management of In-Transit Metastatic Melanoma. <i>Advances in Oncology</i> , 2023, 3, 29-36.	0.2	0

#	ARTICLE	IF	CITATIONS
423	Technical considerations for isolated limb perfusion: A consensus paper. European Journal of Surgical Oncology, 2024, 50, 108050.	1.0	0
424	The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivolLP trial). European Journal of Surgical Oncology, 2024, 50, 108265.	1.0	0